Connect with us

Australia

Emerald Clinics hits record number of patients; joins global fight against COVID-19

Emerald Clinics Ltd (ASX:EMD) continued to make progress against its IPO goals, finishing its June 2020 quarter with record appointment volumes and the expansion of its Real World Evidence technology platform beyond cannabinoids.

The healthcare technology and services company has also joined in the global fight against the COVID-19 pandemic, taking the lead as program manager for the development of a National Clinical Data and Analytical Platform (CDAP) of COVID-19 patient cases to collect clinical data from confirmed COVID-19 patients, from a variety of sources, in close to real-time.

Emerald Clinics chief executive officer Michael Winlo said: “Our strong end to 2020 is pleasing, given the challenges posed by COVID-19 to both patients and our clients. We continue to make progress against our IPO goals, see increasing numbers of patients and new referrals each month and also invest in new and innovative patient monitoring technologies, that both assists patients and increases the val..

Emerald Clinics Ltd (ASX:EMD) continued to make progress against its IPO goals, finishing its June 2020 quarter with record appointment volumes and the expansion of its Real World Evidence technology platform beyond cannabinoids.

The healthcare technology and services company has also joined in the global fight against the COVID-19 pandemic, taking the lead as program manager for the development of a National Clinical Data and Analytical Platform (CDAP) of COVID-19 patient cases to collect clinical data from confirmed COVID-19 patients, from a variety of sources, in close to real-time.

Emerald Clinics chief executive officer Michael Winlo said: “Our strong end to 2020 is pleasing, given the challenges posed by COVID-19 to both patients and our clients. We continue to make progress against our IPO goals, see increasing numbers of patients and new referrals each month and also invest in new and innovative patient monitoring technologies, that both assists patients and increases the value of our data assets.

“We are also being recognised for our thought-leadership in the Real World Evidence (RWE) space through earning key roles in a number of COVID-related projects.

“We look forward to continued growth, expanding our data deals and further developing our Openly offering in the year ahead.”

Expansion of digital health platform Openly


Emerald signed new agreements to enhance its current data capture technology platform and support the launch of a new digital health and clinical monitoring service, Openly, formerly known as Sentinel Plus.

It has secured an agreement with artificial intelligence technology provider Binah.ai to incorporate its world-leading smartphone technology, enabling the collection of contactless vital signs, into Emeralds RWE platform.

The enhanced platform will allow Emerald to incorporate vital signs alongside other clinical and symptom data already collected, through Emeralds existing RWE platform.

This platform increases the depth of clinical evidence captured from Emeralds patients and, when validated, could support companies, universities, governments and other large populations to screen and monitor the health of their personnel remotely, as communities re-open internationally.

The application of Artificial Intelligence (AI) functionality also allows the monitoring system to learn and adapt the screening and care pathway capabilities of the Openly system.

Emerald is targeting organisations in Australia and the US for implementation of Openly, where transmission of COVID-19 remains a challenge to safety and productivity.

In addition, the company had also been engaged by Linear Clinical Research to support the remote evaluation of more than 150 volunteer participants over a two-year period for a Phase 1 COVID-19 vaccine study.

Program manager for CDAP COVID-19 response


In May, Emerald Clinics was appointed program manager for the development of a CDAP, a partnership between several Australian state health bodies, the Federal Government and universities.

Data collected are analysed to form predictive models that can support point-of-care decision making by clinicians across likely disease progressions as well as treatment options for each patient.

Emerald Clinics is leading the program management across the entire project including coordinating the data integration efforts across multiple health services and the analytical model design.

This initial work order will deliver revenue of $100,000 within 12 months.

The Emerald platform will be managed in close association with frontline clinicians across participating institutions, as well as use state and territory resources and digital capabilities.

The CDAP project focuses on the following goals:

Continue Reading

Australia

Danakali bolsters board with mining technical and project finance experience

Danakali Ltd (ASX:DNK) (LON:DNK) (OTCMKTS:SBMSF) has strengthened its board with technical mining and international investment experience through the appointment of Neil Gregson as a non-executive director.

Gregson is a qualified mining engineer with deep experience in the resources sector and he has more than 30 years of experience as an investment manager predominantly in the mining and energy sectors.

Board transition[hhmc]
The appointment comes as part of a board transition as the company moves towards development of the world-class Colluli Sulphate of Potash (SOP) Project in Eritrea.

This process has also seen the retirement of Paul Donaldson and Andre Liebenberg as directors although Donaldson will remain actively engaged with Danakali as a senior consultant.

“Exciting time”[hhmc]
Danakali chairman Seamus Cornelius said: “I am very pleased that Neil Gregson with his wealth of experience in mining and project finance has agreed to join the Danakali board at a very exciting tim..

Danakali Ltd (ASX:DNK) (LON:DNK) (OTCMKTS:SBMSF) has strengthened its board with technical mining and international investment experience through the appointment of Neil Gregson as a non-executive director.

Gregson is a qualified mining engineer with deep experience in the resources sector and he has more than 30 years of experience as an investment manager predominantly in the mining and energy sectors.

Board transition


The appointment comes as part of a board transition as the company moves towards development of the world-class Colluli Sulphate of Potash (SOP) Project in Eritrea.

This process has also seen the retirement of Paul Donaldson and Andre Liebenberg as directors although Donaldson will remain actively engaged with Danakali as a senior consultant.

"Exciting time"


Danakali chairman Seamus Cornelius said: “I am very pleased that Neil Gregson with his wealth of experience in mining and project finance has agreed to join the Danakali board at a very exciting time for the company.

"We look forward to benefitting from Neils involvement as we complete the funding package and bring the Colluli project into production as quickly and safely as possible for the benefit of all stakeholders."

Gregsons most recent role was as portfolio manager at JP Morgan Asset Management Global Equities Team based in London where he was responsible for global natural resources mandates.

He held prior investment management roles at CQS Asset Management as a senior portfolio manager focused on natural resources and at Credit Suisse as head of Emerging Markets and related sector funds.

Former company CEO


Donaldson has been a highly valued board member and previously held the role as CEO of Danakali.

He was instrumental in guiding the company through the early study stages of its development and the high-quality comprehensive FEED study and was closely involved in establishing the Colluli Mining Share Company (CMSC).

He has been a valuable resource to the company and will continue to provide his expertise.

Liebenberg has been a valued boRead More – Source

Continue Reading

Australia

THC Global plans to accelerate medicinal cannabis production on back of strong June quarter

THC Global Group Ltd (ASX:THC) reached several milestones in the June quarter, supplying its first Australian patient with Canndeo branded medicinal cannabis medicines produced at its Southport Facility.

The roll-out of the full suite of the Canndeo medicines range is continuing throughout this quarter and will see the launch of eight new medicine formulations for Australian patients.

THC is also preparing for its maiden export of Canndeo branded medicines to Europe and Canada, with supply expected to commence in quarter three for Canada and quarter four for Europe.

New Zealand exports[hhmc]
In addition to medicinal cannabis sales under the Canndeo brand, THC is now a manufacturer for both Cannatrek and Medleaf Therapeutics.

Under the agreements with Cannatrek and Medleaf, THC will produce and white-label cannabis medicines under those respective brands for sale in the Australian and New Zealand market.

The initial export order to New Zealand worth $260,000 is expected to be deliv..

THC Global Group Ltd (ASX:THC) reached several milestones in the June quarter, supplying its first Australian patient with Canndeo branded medicinal cannabis medicines produced at its Southport Facility.

The roll-out of the full suite of the Canndeo medicines range is continuing throughout this quarter and will see the launch of eight new medicine formulations for Australian patients.

THC is also preparing for its maiden export of Canndeo branded medicines to Europe and Canada, with supply expected to commence in quarter three for Canada and quarter four for Europe.

New Zealand exports


In addition to medicinal cannabis sales under the Canndeo brand, THC is now a manufacturer for both Cannatrek and Medleaf Therapeutics.

Under the agreements with Cannatrek and Medleaf, THC will produce and white-label cannabis medicines under those respective brands for sale in the Australian and New Zealand market.

The initial export order to New Zealand worth $260,000 is expected to be delivered by the company in October.

Tetra Health


The Companys newly acquired clinic network, Tetra Health, has seen significant growth since acquisition with an increase of over 30% in patient enquiries in June alone.

Tetra Health is a key strategic asset for the company in seeking to bridge the affordability gap for cannabis medicines in Australia by providing low cost of access for new patients and product-independent guidance on medicines.

Hydroponics equipment


As announced in early July, the companys hydroponics equipment and cultivation solutions provider achieved its maiden $3 million unaudited half-year trading revenue milestone in June 2020, with total first half 2020 unaudited revenue reaching $3.2 million, being around a 50% increase over the prior period.

The launch of new product and service offerings targeted at the micro-cultivator and home-cultivator sectors through the year is expected to drive further revenue growth.

Difficulties in sourcing and transporting of merchandise from major Asian manufacturing hubs experienced in quarter one due to COVID-19 appear to have partially subsided over quarter two.

As the company noted in its quarter one update, these delays have affected the timing of cash receipts from customers but is unlikely to significantly affect revenue over a longer time scale given pending customer orders are fulfilled as stock is landed in Canada.

THC is preparing for its maiden export of Canndeo branded medicines to Europe and Canada

$8.1 million capital raising


During the quarter, the company completed an institutional placement to raise $6.6 million and a subsequent share purchase plan which raised a further $1.5 million, taking the total capital raised to $8.1 million at 30 cents per share.

Funds will be primarily applied towards enhancing the THCs working cRead More – Source

Continue Reading

Australia

Yandal Resources completes shortfall in $3.3 million non-renounceable rights issue

Yandal Resources Ltd (ASX:YRL) has issued the remaining shortfall shares under the 1 for 5 non-renounceable pro-rata rights issue to raise a total of $3.3 million before costs.

On June 12, the company directors announced a pro-rata non-renounceable rights offer to accelerate the Gordons project as well as the Mt McClure project in Western Australia.

Under the rights issue, eligible shareholders were offered the opportunity to acquire one new share for every five shares held at the record date on June 17 at an issue price of 25 cents per new share.

A total of 1.32 million shortfall shares have now been issued for $330,000

Exploration well-funded[hhmc]
The company plans to progress the feasibility study at its Flushing Meadows prospect at the Ironstone Well Project in the September quarter.

Exploration will also continue at the Gordons Dam prospect.

Yandal is well funded for drill programs which were postponed in the June quarter and will be completed in the September quarter.

The..

Yandal Resources Ltd (ASX:YRL) has issued the remaining shortfall shares under the 1 for 5 non-renounceable pro-rata rights issue to raise a total of $3.3 million before costs.

On June 12, the company directors announced a pro-rata non-renounceable rights offer to accelerate the Gordons project as well as the Mt McClure project in Western Australia.

Under the rights issue, eligible shareholders were offered the opportunity to acquire one new share for every five shares held at the record date on June 17 at an issue price of 25 cents per new share.

A total of 1.32 million shortfall shares have now been issued for $330,000

Exploration well-funded


The company plans to progress the feasibility study at its Flushing Meadows prospect at the Ironstone Well Project in the September quarter.

Exploration will also continue at the Gordons Dam prospect.

Yandal is well funded for drill programs which were postponed in the June quarter and will be completed in the September quarter.

These include:

  • 21 AC holes for 2,500 metres at the Flushing Meadows North prospect;
  • 6 AC holes for 720 metres at the Flushing Meadows South prospect;
  • 3 RC holes for 200 metres Read More – Source
Continue Reading

Trending